

INVITED REVIEW

Microbiomes in respiratory health and disease: An Asia-Pacific perspective

SANJAY H. CHOTIRMALL ^{1*}, SHAAN L. GELLATLY,² KURTIS F. BUDDEN,² MICHEÁL MAC AOGÁIN,¹
SHAKTI D. SHUKLA,² DAVID L.A. WOOD,³ PHILIP HUGENHOLTZ,³ KEVIN PETHE¹ AND
PHILIP M. HANSBRO^{2*},

¹Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore, ²Priority Research Centre for Healthy Lungs, University of Newcastle and Hunter Medical Research Institute, Newcastle, New South Wales and ³Australian Centre for Ecogenomics, School of Chemistry and Molecular Biosciences and Institute for Molecular Bioscience, The University of Queensland, Brisbane, Queensland, Australia

ABSTRACT

There is currently enormous interest in studying the role of the microbiome in health and disease. Microbiome's role is increasingly being applied to respiratory diseases, in particular COPD, asthma, cystic fibrosis and bronchiectasis. The changes in respiratory microbiomes that occur in these diseases and how they are modified by environmental challenges such as cigarette smoke, air pollution and infection are being elucidated. There is also emerging evidence that gut microbiomes play a role in lung diseases through the modulation of systemic immune responses and can be modified by diet and antibiotic treatment. There are issues that are particular to the Asia-Pacific region involving diet and prevalence of specific respiratory diseases. Each of these issues is further complicated by the effects of ageing. The challenges now are to elucidate the cause and effect relationships between changes in microbiomes and respiratory diseases and how to translate these into new treatments and clinical care. Here we review the current understanding and progression in these areas.

Key words: asthma, chronic obstructive pulmonary disease, cystic fibrosis, gut, health, microbiome, mouse model, prevention, respiratory disease, treatment.

Abbreviations: CF, cystic fibrosis; COPD, chronic obstructive pulmonary disease; FMT, faecal microbiota transplantation; GI, gastrointestinal; IBD, inflammatory bowel disease; IL, interleukin; LPS, lipopolysaccharide; SCFA, short-chain fatty acid; TNF- α , tumour necrosis factor alpha.

INTRODUCTION TO THE MICROBIOME—RESPIRATORY AND GUT

In humans, the term 'microbiome' refers to the entire microbial constituents in a given organ or system, including the microorganisms, their genomes, surrounding environmental conditions and their interactions with the host.¹ The gastrointestinal (GI) microbiome is by far the largest in the body, containing more than 100 trillion microbes from over 1000 species.^{2,3} Highly dynamic, the GI microbiome rapidly matures from an *Actinobacteria*-dominated composition soon after birth into the adult microbiome comprising largely of *Firmicutes* and *Bacteroidetes*, as well as *Proteobacteria* and *Actinobacteria* in lower proportions.^{4–7} Given the enormous variety of microbial species and high variability in microbiome composition between individuals, it is likely that different taxa in different individuals can fulfil similar roles in their interactions and metabolism, resulting in a common 'functional microbiome'.⁴

The GI microbiome is the best studied, which results from the abundance of microorganisms and relative ease of sampling via faeces. In contrast, the respiratory microbiome has only recently been characterized through culture-independent techniques such as 16S rRNA sequencing. The respiratory microbiome is dominated by the same major phyla as the GI microbiome, including *Firmicutes*, *Bacteroidetes* and *Proteobacteria*, but with different relative abundances and a reduced total bacterial burden.^{8–15} The lower respiratory microbiome is frequently compared to that of surrounding sites for microbial entry into the lungs, such as the upper respiratory tract, oral cavity and upper GI tract, and is most similar to oral microbiomes.^{10,11} Although translocation and aspiration of microorganisms from these sites are a major source of microbes in the lower respiratory microbiome,^{9–12} the bi-directional movement of matter (inhalation/exhalation) coupled with robust and rapid immune responses has led some to hypothesize that the microorganisms of the respiratory

Correspondence: Philip M. Hansbro, Hunter Medical Research Institute, Lot 1 Kookaburra Circuit, New Lambton Heights, NSW 2305, Australia. Email: philip.hansbro@newcastle.edu.au

*S.H.C. and P.M.H. have equally shared responsibility for this study.

Received 28 June 2016; invited to revise 1 August 2016; revised 30 October 2016; accepted 17 November 2016 (Associate Editor: Chi Chiu Leung).

microbiome are not resident and growing populations, but are rather continuously recolonizing the lower respiratory tract from surrounding sites in a dynamic and transient manner.^{10,16,17} Nevertheless, the respiratory microbiome is distinct from that of surrounding sites, characterized by the enrichment of *Proteobacteria* and reduced abundance of *Prevotella* species.^{8–13}

With greater understanding of the microbiome, its biological role at both local and distal sites has become increasingly well recognized. In this review, we explore the role of the GI and respiratory microbiomes in health and disease specifically in the Asia-Pacific region, as well as the future of microbiome research in clinical practice in this area.

RESPIRATORY DISEASE AND THE MICROBIOME

Microbes and their host interact in an intricate and generally beneficial relationship. Conversely, the disturbance of the microbiome (i.e. dysbiosis) is commonly linked to the increased risk and severity of many diseases including those of the respiratory tract. A critical role in normal development has been demonstrated in germ-free mice, which lack any resident microbes and have underdeveloped immune systems, anatomical and histological alterations and significant digestive and metabolic disturbances. However, a healthy state can be restored in these mice by inoculation with resident GI microbes, such as through faecal transfer.^{5,18} While germ-free mice are an extreme case, factors such as age, diet and antibiotic use have been shown to maintain or impact the risk and outcomes of disease through alterations to microbiome composition.^{19,20} Conversely, the onset of disease may cause microbial dysbiosis at either local or distant body sites, which may in turn contribute to promoting the pathogenesis of disease.

Patients with chronic respiratory disease are two to three times more likely to have GI issues, while over half of inflammatory bowel disease (IBD) patients display pulmonary involvement.^{21–23} These peripheral manifestations of disease highlight the immunological crosstalk between these two mucosal sites, termed the ‘gut-lung axis’, whereby the immunological health of the gut impacts upon the health of the lung.²³ The GI and respiratory microbiomes are thought to play a major role in this axis as both are altered in chronic respiratory diseases, including COPD,^{8,24,25} asthma^{14,15,26} and cystic fibrosis (CF).^{8,27} This may involve the activation of inflammasomes, microRNAs and numerous other factors.^{28–31} In disease, similar selective pressures caused by conditions in the local environment may occur at both sites, resulting in similar (but not identical) changes to microbiome composition. For example, a greater abundance of *Proteobacteria* was observed in both the faeces of smokers²⁴ and lung brushings of COPD patients,¹⁴ although variability between subjects confounds comparisons of separate studies. To date few, if any, investigations have simultaneously characterized both the GI and pulmonary microbiomes in respiratory disease and so direct comparisons are difficult.

The GI microbiome affects the risk and/or outcomes of experimental respiratory infections and chronic respiratory disease through the modulation of pulmonary immune responses.^{20,32–35} It has also been implicated in GI pathology following pulmonary infection, with immune cells migrating from the lungs causing microbial dysbiosis and subsequently aberrant immune responses.³⁶ While the influence of the respiratory microbiome on immune responses is less well characterized, it may act as a reservoir for infections caused by *Proteobacteria* (e.g. *Haemophilus* species) in asthma and COPD^{14,25,37–39} or *Pseudomonas* colonization in CF.⁸ Modulation of the microbiome by prebiotic and probiotic treatment has significant benefits in the prevention and treatment of respiratory disease, although further studies are required for translation to clinical use.^{20,34,35,40,41}

THE ASIA-PACIFIC REGION AND THE MICROBIOME

The Asia-Pacific region is a large geographic area with substantial ethnic, cultural and genetic diversity.⁴² Definitions of the region vary. We have used that of Jamrozik and Musk that divides countries based on income, since this has been extensively used in prior analysis of respiratory disease in this region.⁴³ The significant heterogeneity of the region is reflected in the growing number of Asia-Pacific microbiome studies that reveal microbial profiles shaped by ethnogeography, diet and host genetics. These studies show that patterns and differences relative to Western and European studies are emerging (Fig. 1). Diet and country of origin have strong influences on the microbiome and have been observed to correlate with gut microbiota composition in school children from several Asia-Pacific countries.⁵¹ Furthermore, the dynamics of Mongolian microbiome signatures highlight reconfigurations associated with seasonal dietary changes.⁵²

The Jamrozik and Musk definition includes Australia and New Zealand. These represent high-income countries with Western diets and microbiomes distinct to those found in other areas of the Asia-Pacific region. It is thought that Australia and New Zealand bear greater similarity to that of European rather than Asian populations. Additional heterogeneity in the Asia-Pacific comes from host genetics and evidence for its influence on the microbiome in the region is clearly emerging. This includes a recent Korean monozygotic twin study that shows the complex interaction between host and microbiome.⁵² Other factors such as nutritional status and cigarette smoking—a key causative agent for chronic respiratory disease—have been shown to directly influence the microbiome in India, China and Korea.^{47,53,54} Socioeconomic status and urbanization were also important predictors of microbiome composition in Malaysia, Thailand and Russia.^{48,51,55} In an analysis of bacterial gut diversity in school-aged children from five Asia-Pacific countries, Nakayama *et al.*, noted a high abundance of *Bifidobacteria* (species belonging to the genus *Bifidobacterium*), a trend previously identified in rural Russian and central Asian populations.^{51,55} Clear segregation into two distinct




Figure 1 Summary of the established microbiome variations identified between Western and the Asia-Pacific and other countries shaped by differences in ethnogeography, diet and host genetics. While studies are limited, and further work required, a number of trends are emerging from early studies. Studies supporting these trends are cited in the figure.

enterotype-like clusters was observed: one similar to the *Prevotella* enterotype described in European populations and a second representing a novel *Bifidobacteria*-rich microbiome ostensibly associated with carbohydrate-based Asian diets (Fig. 1).⁵¹ Other studies have linked fermented foods such as Japanese fermented milk products and Korean kimchi to specific alterations in the microbiota including increased abundance of such *Bifidobacteria*.^{56,57}

Commensal *Bifidobacteria* can induce altered immune responses and are abundant in early life among Western populations but decline with age.^{58,59} As the sustained prevalence of this bacterial group represents the most discernible difference between Asia-Pacific and Western microbiomes, it is interesting to speculate about its potential contribution to geographic variability in the rates of inflammatory diseases including those of the respiratory system. Regional data are also consistent with a negative correlation among gut *Bacteroidetes* to *Firmicutes* ratios with respect to latitude.⁶⁰ This trend likely reflects the environmental and dietary covariates of latitude that impact upon the microbiome. The trend is also evident in the Asia-Pacific region, although important exceptions exist. Mongolia has a northerly latitude and much colder average yearly temperatures yet the population exhibits a notably higher *Bacteroidetes* to *Firmicutes* ratio relative to other Asia-Pacific countries.^{51,52} Such contrasts suggest that further refinements of this concept are warranted. Despite this, the microbiome composition in the community is strongly context dependent and heavily influenced by geographic location.^{59,61}

Oral microbiome studies in the Asia-Pacific region have uncovered additional ethnogeographic differences among Japanese and Koreans that were correlated with susceptibility to periodontitis.⁶² Furthermore, metagenomic analysis of Chinese subjects provided a clear demonstration of the influence of plaque microbiota on gingival inflammation.⁴⁶ Intriguingly, oral, salivary and gut microbiomes of Chinese patients suffering from rheumatoid arthritis—an autoimmune condition

with respiratory manifestations—were significantly altered compared to controls.^{44,45,63} Thus changes in the gut microbiome related to local diets, geography or other environmental effects in the Asia-Pacific may induce changes in physiology at distal body sites or vice versa, including the lung, and thus contribute to respiratory disease.^{23,49} As such, studies of the gut and oral microbiota performed in our region improve our understanding of the development and progression of respiratory diseases that afflict populations in this region and contribute to global understanding. While direct metagenomic investigations of the airway microbiome in Asian populations are limited, several studies have emerged that have assessed diseases of increased regional prevalence such as non-CF bronchiectasis, *Mycobacterium tuberculosis* infection and lung cancer.^{50,64–66} In the most comprehensive of these studies, Rogers *et al.* defined the airway microbiome of Australian non-CF bronchiectasis patients.⁶⁷ Importantly, lung microbiome composition correlated with lung function and permitted more refined stratification of patients into risk groups, with increasing risk of future exacerbations, compared to conventional diagnostic methodologies.⁶⁸ This remains the largest culture-independent molecular study of the lungs performed in the Asia-Pacific region to-date and provides a framework for future studies both within this area and globally.

Many diseases of particular relevance to the Asia-Pacific region including COPD, asthma, tuberculosis and lung cancer have now begun to be assessed in metagenomic studies using high-throughput sequencing.^{19,21,50,65} These diseases have been directly linked to environmental exposures such as cigarette smoke, air pollution and occupational carcinogens. All these factors are of increasing importance in the Asia-Pacific region and have the potential to significantly alter the gut and lung microbiomes.^{11,43,47,65} In addition, other diseases that are specific to the Asia-Pacific, such as diffuse pan-bronchiolitis, are also likely to involve an alteration in microbiomes, although this remains to be

investigated from a metagenomic perspective.⁶⁹ Given the indication of macrolides as therapeutics in this disease, an analysis of the microbiota in macrolide-treated patients would be of interest and may reveal parallels with the remodeling of the microbiota seen in macrolide-treated bronchiectasis.^{67,70} The investigation of these Asia-Pacific respiratory health issues on a larger-scale particularly with the power of metagenomic studies will provide greater insight into the phenotype of respiratory disease observed in this region.

PAST AND PRESENT PERSPECTIVE ON EVOLUTION OF THE MICROBIOME

Respiratory and gut microbiomes in health

The microbiome has been implicated in several aspects of health, including acting as a direct competitor for pathogens, instructing the development of the immune system and the production of beneficial metabolites (e.g. vitamins, essential amino acids and short-chain fatty acids (SCFAs)). However, defining what constitutes a healthy microbiome in either the GI or respiratory tracts is a key concept that is still being satisfactorily clarified. While bacteria belonging to the phyla *Bacteroidetes* and *Firmicutes* make up the largest component of both GI and respiratory microbiota,^{21,71} there is increased variation at lower taxonomic ranks, to the extent that a bacterial species present in one healthy individual may not be detectable in another. This is more pronounced for the respiratory tract. Moreover, the microbiome is plastic, adapting to changes in its environment (e.g. diet). This leads to the concept of a 'functional microbiome', where the influence of the microbiome on health and disease is less dependent on any one species of bacteria but rather on the presence of microbes that can facilitate a particular function, such as the fermentation of dietary fibre by *Bifidobacterium* sp. and *Faecalibacterium prausnitzii* to make SCFAs, which in turn serve as energy sources for colonic cells and as anti-inflammatory agents.⁷²

The importance of the GI microbiota in digestion, intestinal homeostasis and organ and immune system development are broadly recognized. How the microbiome contributes to normal immune system and organ development is not yet clear. Bacterial antigens such as LPS and peptidoglycan trigger immune responses through pattern recognition receptors such as toll-like receptors and drive the proliferation of B- and T-cells in peripheral lymphoid tissue, contributing to the development of oral and systemic tolerance.^{73–75} Microbial metabolites, such as vitamins and SCFAs, act in concert with host metabolism and can have additional direct effects on host immunity. Indole, a derivative of tryptophan produced by several microbial species has been linked to increased barrier function in colonic epithelial cells.⁷⁶ SCFAs, the most studied bacterial metabolites, have been linked to protection from infection, energy sources for colonic epithelial cells as well as modulation of inflammatory responses through free-fatty acid receptor 2.^{77,78}

While the microbiota of the GI tract has been extensively studied, few have investigated microbial

communities of the respiratory tract or how GI microbiota might affect extra-intestinal sites. Recent studies have shown that microorganisms are detectable in the healthy lung with culture-independent techniques. It is distinct from the microbiota found within the oral cavity, upper respiratory tract or nasal cavity, the most likely sites of microbial entry to the lungs and is most similar to oral microbiomes.^{10,11}

Respiratory and gut microbiomes in disease

Many studies now show that a change in composition of respiratory and gut microbiomes and dysbiosis is associated with disease. However, identifying the changes in microbiota that cause disease, rather than those that occur as a consequence of disease, remains challenging. It is becoming increasingly clear that a dysregulated gut-lung axis plays a role in respiratory disease. This has been most widely linked to the development of asthma. Epidemiological studies demonstrate a steady increase in the incidence of allergic disease, including asthma, in developed countries and together with recent experimental data suggest that a lack of proper exposure to varied, mostly gut-associated microbes, in early life may be a contributing factor.^{35,79,80} Knowledge of the lung microbiota and how it influences lung health remains limited.⁸¹ Manipulations of the gut microbiome in a bid to maintain or restore gut health is not a new concept. Probiotic formulations are sold over the counter with promises to maintain and restore digestive health and boost immunity while some yogurt is now similarly marketed. Whole community faecal microbiota transplantation (FMT), whereby faeces from a healthy donor is used to replenish or replace the microbiota of someone who is ill, had its first report in fourth century China and was rediscovered by modern medicine in the 1950s.^{82,83} The best-documented change in microbiota causing disease is that of antibiotic-induced outgrowth of *C. difficile*. Human patients suffering from a *C. difficile* infection-induced colitis seek frequent healthcare and often take courses of antibiotics.⁸⁴ Antibiotics can disrupt both the overall microbial abundance and the community composition causing a change in the microbiome's functionality, particularly its ability to resist and compete with potential pathogenic microorganisms, such as *C. difficile*. FMT has been used with great success (90%) to restore the normal function of the microbiota to resist enteric pathogens in both the clinic and in animal models of antibiotic-induced pseudomembranous colitis.^{84–86}

Antibiotics have also been implicated in the development of asthma. Children exposed to antibiotics in utero are at increased risk of developing asthma, as are those who are exposed to antibiotics within the first year of life, although to a lesser extent.⁸⁷ This is supported by data derived from animal models, which show that mice exposed as neonates to vancomycin but not streptomycin developed more severe allergic airways disease when challenged with ovalbumin. Colonic CD4⁺CD25⁺Foxp3⁺ Tregs, which are known to be induced by several species of commensal bacteria,⁷⁵ were reduced in the vancomycin-treated animals.¹⁹ This revealed that not only can antibiotic-induced

changes in microbiota alter the immune response, but that these changes are antibiotic specific. Indeed we have recently shown that both the anti-inflammatory and antibiotic properties of macrolides are needed to effectively suppress severe allergic airway disease.⁸⁸ In other studies, faeces were transplanted from human infants with atopic wheeze into mice whose subsequent offspring developed more severe allergic airways. Four bacterial species were identified to be absent from the infants with atopic wheeze, which when supplemented into faeces, could protect mice from developing severe allergic airways disease.³⁵

Environmental factors can also shape the microbiome and affect disease susceptibility. Cigarette smoking is the strongest risk factor for developing COPD as well as Crohn's disease.²³ Indeed it is broadly accepted that COPD is associated with intestinal manifestations, such as decreased gut integrity and nutritional absorptivity.^{23,89} Although there are few studies, COPD patients have been shown to have altered lung microbiota compared to healthy smokers,⁸ and one study has shown that cigarette smoking itself affects the composition of gut microbiota.⁹⁰ Air pollution also has effects on the respiratory system and exposure is associated with lung cancer, COPD and asthma exacerbations.⁹¹ While the association of air pollution to the microbiota has not been widely studied, ingested particulate matter has been shown to alter the faecal microbiota and increase intestinal inflammation in mice,^{92,93} and a small study of sputum microbiota from never-smokers residing in two regions within the same Chinese county revealed different microbial profiles associated with the two types of coal burned in those locations.⁶⁵ These strong associative links between smoke- and pollution-induced changes to the gut and lung microbiome and respiratory disease warrant further investigation. Nevertheless, it will be difficult to demonstrate whether the microbiome changes are a cause or result of lung disease, or perhaps one of the contributing factors and further research is needed in this area.

FUTURE PERSPECTIVES OF THE MICROBIOME

Antibiotic resistance and the microbiome

Recent large-scale studies have revealed unexpected links between microbiome structure, function and pathological disease. Many bacteria are harmless in a healthy system but can cause disease when the normal balance is compromised following exogenous infection, antibiotic treatment or immune modulation. What is also emerging is the role of commensal microbiota as a reservoir of antibiotic resistance genes. Antimicrobial resistance, while considered an emerging problem in modern medicine, is actually an ancient phenomenon deeply encoded in bacterial genomes from all ecological niches.⁹⁴ It should therefore be of no surprise that the human microbiome contains numerous and diverse sets of antibiotic resistance genes,⁹⁰ often organized in integrons that facilitate exchange between bacteria.⁹⁵ In addition to this natural phenomenon, escalating antibiotic selective pressure has increased

the proportion of commensal bacteria carrying antibiotic resistance genes^{96,97} that may further be transmitted to opportunistic pathogens. In animal models, treatment of lung infections with high-dose antibiotics rapidly selects for resistant microorganisms in the gut microbiome,⁹⁸ illustrating that treatment of a local infection impacts upon bacterial population structure and antimicrobial resistance at distal sites. Interestingly, decreasing the dose of antibiotics has a limited effect on the expansion of drug-resistant bacteria in the gut microbiota,⁹⁸ an observation that may hold important clinical relevance.

Transmission of antibiotic resistance genes between microbiota is facilitated by mobile elements such as integrons, transposons, bacteriophages⁹⁹ and even outer membrane vesicle release.¹⁰⁰ A high proportion of bacteria are infected by prophages that are induced and released under stress conditions, including antibiotic treatment,¹⁰¹ further accelerating gene dissemination and antibiotic resistance among related bacteria. This issue is particularly well-illustrated in CF where patients receive frequent doses of antibiotics to treat chronic polymicrobial lung infections. Metagenomic analyses reveal a specific bacteriophage community in CF patients¹⁰² that participate in the persistence and dissemination of multiple antimicrobial resistance genes.¹⁰³ This is correlated with the observation that the complex, pathological, respiratory microbiota in CF is highly resistant and resilient to antibiotic treatment.^{104,105} Since the presence of *Pseudomonas aeruginosa* is associated with poor clinical outcome in these patients,^{106–108} antibiotic treatment is typically designed to target this pathogen. Interestingly, a clinical study revealed that *P. aeruginosa* was not only largely resistant to antibiotic treatment, its relative abundance even increased significantly with treatment during episodes of pulmonary exacerbations, which may result from reduced competition with resident respiratory microbiota.¹⁰⁵

The emergence and persistence of antibiotic resistance genes is a complex process that should be considered from an ecological perspective to be driven by complex interactions between the commensal, pathobiont and pathogenic bacteria composing our microbiome. This view advocates for the development of narrow-spectrum antibacterial agents that are less likely to disturb the ecology of the core microbiota or promote the transfer of resistance genes across bacterial species.

Ageing and the microbiome

As we age, so do our microbiota, promoting change within it.^{109,110} In the gut, transition from a variable to stable microbiome occurs in the first 3 years of life.⁵⁹ During this period our immune system interacts with and is likely influenced by commensal microbes.¹¹¹ Interactions with such commensals are essential for normal immune development and have key roles in the development of a healthy immune system in later life.⁵⁸ This is reflected in animal studies where disruption of gut microbiota leads to subsequent inflammatory airway disease.^{112,113} This translates well to human studies where reduced gut diversity in early life

predicts subsequent development of asthma in school children.¹¹⁴

During ageing the alterations in our microbiomes closely correlate with increases in pro-inflammatory markers, particularly in the elderly, including TNF- α , IL-6, IL-8 and C-reactive protein. Interestingly, increasing levels of IL-6 and IL-8 with age are associated with the enrichment of *Proteobacteria* and declines in butyrate-producing bacteria.^{109,110}

Evidently, the gut microbiome has a significant bearing on respiratory disease and vice versa. Further, its influence on the immune system likely underpins many facets of airway inflammation and infection that evolve with age and immunosenescence.^{49,115,116} The emerging role of the microbiome in shaping our immune system and its loss of function with age may provide a context for understanding the impact of age-associated immunosenescence and 'inflamm-ageing' on respiratory diseases such as COPD, late-onset asthma and pulmonary fibrosis.^{49,116,117} The most extensive investigation of age-related effects on the pulmonary microbiome has been performed in CF patients revealing a decline in lung microbiome diversity with both age and lung function.¹¹⁸ However, an authoritative metagenomic analysis of age as a predictor of the human airway microbiome in healthy subjects, such as that performed by Yatunen *et al.* in the gut, is yet to be undertaken.⁵⁹ Our understanding of the respiratory microbiome as a function of age thus remains largely unexplored. This is coupled with the knowledge that the interplay between the microbiome and immune system is important and continues to reveal novel interactions. Respiratory microbiota could exist as a stable entity that is modified over time or is transient with continual re-seeding from the environment and cleared by immune responses and could be defined as a set of microbial genes rather than species. Nevertheless, defining respiratory microbiota throughout different stages of life is likely to advance our understanding of age-related lung disease such as COPD, asthma, pulmonary fibrosis, bronchiectasis and CF, offering opportunities for novel diagnostic aids and therapeutic approaches.⁴⁹

Elucidating relationships between microbiomes and health and disease

Many studies of the roles of microbiomes in health and disease come from the cross-sectional assessment of clinical samples. This identifies associations but not causal relationships.²¹ Mechanistic interactions can be elucidated in prospective human studies but these are long-term, expensive and affected by inherent genetic and environmental variabilities, meaning that they need to be undertaken on a large-scale.³⁵ Animal models are valuable in elucidating these relationships. They are genetically uniform; diets and environments can be tightly controlled; and are relatively quick and inexpensive experiments to perform. They can then be associated with changes in human disease and even if the precise taxa involved are not the same, but as they play similar functional roles, relationships can be determined. New animal models of COPD, severe asthma and their exacerbations as well as other diseases that closely resemble different human phenotypes have recently been

developed.^{88,119–128} They are therefore likely to be valuable in facilitating the evaluation of relationships between microbiota, health and disease. These can be combined with ex vivo studies using primary cells from humans,¹¹⁹ including with microbial challenge.^{129–131}

How to best translate findings into clinical care practice and bedside application?

A major goal in studying microbiomes is to translate findings into more targeted therapy and ultimately improved patient care. To this end, a promising area of application lies in the ability of microbiome status to predict disease severity and prognosis in respiratory diseases, including COPD, asthma, CF and non-CF bronchiectasis.^{68,114,118,132} Although we are only at the beginning of cataloguing our lung-associated microbiota, signals of disease are clearly emerging, some of which have already been exploited in stratifying patients according to clinical outcomes. Direct clinical application therefore hinges on whether information gained in measuring or quantifying microbiota can stratify patients with greater precision than conventional methods, or indeed recognize novel disease phenotypes that require special attention. Analysis of microbiota in non-CF bronchiectasis for example has shown that community profiling predicts disease, inflammation and disease-related outcomes more accurately than standard detection of known pathogens through conventional culture or even molecular methods.⁶⁸ Further and larger-scale studies that specifically address respiratory disease states are clearly necessary and likely to reveal further information on disease onset, pathogenesis, progression and underlying aetiology.

Knowledge of microbiome composition may be leveraged clinically to identify patients early with a poorer prognostic course and permit targeted and dedicated care.¹³³ Metagenomic analysis reveals clinical and environmental variables that perturb the microbiome (e.g. antimicrobial therapy or infection) and influence patients towards dysbiosis and associated disease states such as the unintended antibiotic-induced development of *Clostridium difficile* infection. Restoration of microbial diversity through FMT has been successful in the gut¹³⁴; however, how this may be applied to the lung remains unclear particularly in the context of complex environments such as chronic lung infection and colonization states. Thus, influencing respiratory disease through the gut-lung axis may be a more realistic and practical approach with early evidence emerging from pre-clinical studies.¹³⁵ Novel approaches such as probiotic therapy, more selective antimicrobial therapy and diet alterations also hold promise. Understanding resulting consequences for infection, immunity and inflammation in the lung using such approaches is an important first step and intervention during early life may therefore have greater impacts on respiratory disease outcomes and prevention as one ages.

CONCLUSIONS

It is now clear that changes in respiratory microbiomes accompany respiratory diseases and these changes are

currently being catalogued. They are impacted by environmental exposures including cigarette and other forms of smoke,⁴³ air pollution and infections, as well as antibiotic treatment. It is emerging that the GI microbiome may also impact the respiratory system, which, in turn are impacted by diet and antibiotics, although the effects are much less clear. The changes in respiratory and gut microbiomes could be a consequence of the development of disease or they could be a causal factor. Changes in inflammatory and immune responses in disease could be the cause of these changes. Conversely, alterations in microbiomes could alter the factors that they release including bacterial components and metabolites such as SCFAs that alter the pro- and anti-inflammatory balance. There are specific issues at play in the Asia-Pacific region with the prevalence of particular diets, respiratory diseases and latitudinal effects. Although to date numerous associational studies have been undertaken there have been few causal studies. These could involve long-term prospective clinical studies and studies with animal models that accurately reflect disease features and work with primary human cells ex vivo. There is the real potential for disease modification using microbiome alterations with FMT, diets or targeted antibiotics and as the field progresses these could be new therapeutic options for respiratory disease if they can be translated into the clinic.

Acknowledgements

This research (S.H.C.) is supported by the Singapore Ministry of Health's National Medical Research Council under its Transition Award (NMRC/TA/0048/2016). P.M.H. is supported by fellowships and grants from the National Health and Medical Research Council of Australia, the Brawn Foundation of the Faculty of Health and Medicine, University of Newcastle and the Rainbow Foundation. We thank F. Thomson and M. Thomson for their continued support.

REFERENCES

- Marchesi JR, Ravel J. The vocabulary of microbiome research: a proposal. *Microbiome* 2015; **3**: 31.
- Zeng H, Lazarova DL, Bordonaro M. Mechanisms linking dietary fiber, gut microbiota and colon cancer. *World J. Gastrointest. Oncol.* 2014; **6**: 41–51.
- Fagundes CT, Souza DG, Nicoli JR, Teixeira MM. Control of host inflammatory responsiveness by indigenous microbiota reveals an adaptive component of the innate immune system. *Microbes Infect.* 2011; **13**: 1121–32.
- Huttenhower C, Gevers D, Knight R, Abubucker S, Badger JH, Chinwalla AT, Creasy HH, Earl AM, FitzGerald MG, Fulton RS *et al.* Structure, function and diversity of the healthy human microbiome. *Nature* 2012; **486**: 207–14.
- Noverr MC, Huffnagle BG. Does the microbiota regulate immune responses outside the gut? *Trends Microbiol.* 2004; **12**: 562–8.
- Morgan X, Segata N, Huttenhower C. Biodiversity and functional genomics in the human microbiome. *Trends Genet.* 2013; **29**: 51–8.
- Dogra S, Sakwinska O, Soh S, Ngom-Bru C, Bruck W, Berger B, Brussow H, Karnani N, Lee Y, Yap F *et al.* Rate of establishing the gut microbiota in infancy has consequences for future health. *Gut Microbes* 2015; **6**: 321–5.
- Sze MA, Dimitriu PA, Hayashi S, Elliott WM, McDonough JE, Gosselink JV, Cooper J, Sin DD, Mohn WW, Hogg JC. The lung tissue microbiome in chronic obstructive pulmonary disease. *Am. J. Respir. Crit. Care Med.* 2012; **185**: 1073–80.
- Venkataraman A, Bassis CM, Beck JM, Young VB, Curtis JL, Huffnagle GB, Schmidt TM. Application of a neutral community model to assess structuring of the human lung microbiome. *MBio* 2015; **6**: e02284–14.
- Bassis C, Erb-Downward J, Dickson R, Freeman C, Schmidt T, Young V, Beck J, Curtis J, Huffnagle G. Analysis of the upper respiratory tract microbiotas as the source of the lung and gastric microbiotas in healthy individuals. *MBio* 2015; **6**: e00037–15.
- Morris A, Beck J, Schloss P, Campbell T, Crothers K, Curtis J, Flores S, Fontenot A, Ghedin E, Huang L *et al.* Comparison of the respiratory microbiome in healthy nonsmokers and smokers. *Am. J. Respir. Crit. Care Med.* 2013; **187**: 1067–75.
- Dickson R, Huffnagle G. The lung microbiome: new principles for respiratory bacteriology in health and disease. *PLoS Pathog.* 2015; **11**: e1004923.
- Dickson RP, Erb-Downward JR, Huffnagle GB. Homeostasis and its disruption in the lung microbiome. *Am. J. Physiol. Lung Cell. Mol. Physiol.* 2015; **309**: L1047–55.
- Hilty M, Burke C, Pedro H, Cardenas P, Bush A, Bossley C, Davies J, Ervine A, Poulter L, Pachter L *et al.* Disordered microbial communities in asthmatic airways. *PLoS One* 2010; **5**: e8578.
- Goleva E, Jackson L, Harris J, Robertson C, Sutherland E, Hall C, Good J, Gelfand E, Martin R, Leung D. The effects of airway microbiome on corticosteroid responsiveness in asthma. *Am. J. Respir. Crit. Care Med.* 2013; **188**: 1193–201.
- Saeedi P, Salimian J, Ahmadi A, Imani FA. The transient but not resident (TBNR) microbiome: a Yin Yang model for lung immune system. *Inhal. Toxicol.* 2015; **27**: 451–61.
- Budden KF, Gellatly SL, Wood DLA, Cooper MA, Morrison M, Hugenholtz P, Hansbro PM. Emerging pathogenic links between microbiota and the gut-lung axis. *Nat. Rev. Microbiol.* 2016; **15**: 55–63.
- Wymore Brand M, Wannemuehler MJ, Phillips GJ, Proctor A, Overstreet AM, Jergens AE, Orcutt RP, Fox JG. The altered *Schaefferia flora*: continued applications of a defined murine microbial community. *ILAR J.* 2015; **56**: 169–78.
- Russell SL, Gold MJ, Hartmann M, Willing BP, Thorson L, Wlodarska M, Gill N, Blanchet MR, Mohn WW, McNagny KM *et al.* Early life antibiotic-driven changes in microbiota enhance susceptibility to allergic asthma. *EMBO Rep.* 2012; **13**: 440–7.
- Thorburn A, McKenzie C, Shen S, Stanley D, Macia L, Mason L, Roberts L, Wong C, Shim R, Robert R *et al.* Evidence that asthma is a developmental origin disease influenced by maternal diet and bacterial metabolites. *Nat. Commun.* 2015; **6**: 7320.
- Chambers DC, Gellatly SL, Hugenholtz P, Hansbro PM. JTD special edition 'Hot Topics in COPD'—the microbiome in COPD. *J. Thorac. Dis.* 2014; **6**: 1525–31.
- Mateer SW, Maltby S, Marks E, Foster PS, Horvat JC, Hansbro PM, Keely S. Potential mechanisms regulating pulmonary pathology in inflammatory bowel disease. *J. Leukoc. Biol.* 2015; **98**: 727–37.
- Keely S, Talley NJ, Hansbro PM. Pulmonary-intestinal cross-talk in mucosal inflammatory disease. *Mucosal Immunol.* 2012; **5**: 7–18.
- Biedermann L, Brulisaue K, Zeitz J, Frei P, Scharl M, Vavricka SR, Fried M, Loessner MJ, Rogler G, Schuppler M. Smoking cessation alters intestinal microbiota: insights from quantitative investigations on human fecal samples using FISH. *Inflamm. Bowel Dis.* 2014; **20**: 1496–501.
- Pragman A, Kim H, Reilly C, Wendt C, Isaacson R. The lung microbiome in moderate and severe chronic obstructive pulmonary disease. *PLoS One* 2012; **7**: e47305.
- Hevia A, Milani C, López P, Donado CD, Cuervo A, González S, Suárez A, Turróni F, Gueimonde M, Ventura M *et al.* Allergic patients with long-term asthma display low levels of *Bifidobacterium adolescentis*. *PLoS One* 2016; **11**: e0147809.
- Bruzzese E, Callegari M, Raia V, Viscovo S, Scotto R, Ferrari S, Morelli L, Buccigrossi V, Lo Vecchio A, Ruberto E *et al.* Disrupted intestinal microbiota and intestinal inflammation in children with

- cystic fibrosis and its restoration with *Lactobacillus* GG: a randomised clinical trial. *PLoS One* 2014; **9**: e87796.
- 28 Foster PS, Plank M, Collison A, Tay HL, Kaiko GE, Li J, Johnston SL, Hansbro PM, Kumar RK, Yang M *et al.* The emerging role of microRNAs in regulating immune and inflammatory responses in the lung. *Immunol. Rev.* 2013; **253**: 198–215.
 - 29 Kim RY, Horvat JC, Pinkerton JW, Starkey MR, Essilfie AT, Jones B, Haw TJ, Keely S, Mattes J, Adcock IM *et al.* MicroRNA-21 drives severe, steroid-insensitive experimental asthma through phosphoinositide-3-kinase. *J. Allergy Clin. Immunol.* 2016. doi: 10.1016/j.jaci.2016.04.038.
 - 30 Kim RY, Pinkerton JW, Gibson PG, Cooper MA, Horvat JC, Hansbro PM. Inflammasomes in COPD and neutrophilic asthma. *Thorax* 2015; **70**: 1199–201.
 - 31 Tay HL, Kaiko GE, Plank M, Li J, Maltby S, Essilfie AT, Jarnicki A, Yang M, Mattes J, Hansbro PM *et al.* Antagonism of miR-328 increases the antimicrobial function of macrophages and neutrophils and rapid clearance of non-typeable *Haemophilus influenzae* (NTHi) from infected lung. *PLoS Pathog.* 2015; **11**: e1004549.
 - 32 Clarke T. Early innate immunity to bacterial infection in the lung is regulated systemically by the commensal microbiota via Nod-like receptor ligands. *Infect. Immun.* 2014; **82**: 4596–606.
 - 33 Fagundes CT, Amaral FA, Vieira AT, Soares AC, Pinho V, Nicoli JR, Vieira LQ, Teixeira MM, Souza DG. Transient TLR activation restores inflammatory response and ability to control pulmonary bacterial infection in germfree mice. *J. Immunol.* 2012; **188**: 1411–20.
 - 34 Trompette A, Gollwitzer E, Yadava K, Sichelstiel A, Sprenger N, Ngom-Bru C, Blanchard C, Junt J, Nicod L, Harris N *et al.* Gut microbiota metabolism of dietary fibre influences allergic airway disease and hematopoiesis. *Nat. Med.* 2014; **20**: 159–66.
 - 35 Arrieta MC, Stiemsma LT, Dimitriu PA, Thorson L, Russell S, Yurist-Doutsch S, Kuzeljevic B, Gold MJ, Britton HM, Lefebvre DL *et al.* Early infancy microbial and metabolic alterations affect risk of childhood asthma. *Sci. Transl. Med.* 2015; **7**: 307ra152.
 - 36 Wang J, Li F, Wei H, Lian Z, Sun R, Tian Z. Respiratory influenza virus infection induces intestinal immune injury via microbiota-mediated Th17 cell-dependent inflammation. *J. Exp. Med.* 2014; **211**: 2397–410.
 - 37 Larsen J, Musavian H, Butt T, Ingvorsen C, Thysen A, Brix S. Chronic obstructive pulmonary disease and asthma-associated Proteobacteria, but not commensal *Prevotella* spp., promote Toll-like receptor 2-independent lung inflammation and pathology. *Immunology* 2015; **144**: 333–42.
 - 38 Simpson JL, Baines KJ, Horvat JC, Essilfie AT, Brown AC, Tooze M, McDonald VM, Gibson PG, Hansbro PM. COPD is characterized by increased detection of *Haemophilus influenzae*, *Streptococcus pneumoniae* and a deficiency of *Bacillus* species. *Respirology* 2016; **21**: 697–704.
 - 39 Wood LG, Simpson JL, Hansbro PM, Gibson PG. Potentially pathogenic bacteria cultured from the sputum of stable asthmatics are associated with increased 8-isoprostane and airway neutrophilia. *Free Radic. Res.* 2010; **44**: 146–54.
 - 40 King S, Glanville J, Sanders ME, Fitzgerald A, Varley D. Effectiveness of probiotics on the duration of illness in healthy children and adults who develop common acute respiratory infectious conditions: a systematic review and meta-analysis. *Br. J. Nutr.* 2014; **112**: 41–54.
 - 41 Luoto R, Ruuskanen O, Waris M, Kalliomäki M, Salminen S, Isolauri E. Prebiotic and probiotic supplementation prevents rhinovirus infections in preterm infants: a randomized placebo-controlled trial. *J. Allergy Clin. Immunol.* 2014; **133**: 405–13.
 - 42 Hugo Pan-Asian SNP Consortium, Abdulla MA, Ahmed I, Assawamakin A, Bhak J, Brahmachari SK, Calacal GC, Chaurasia A, Chen CH, Chen J *et al.*; Indian Genome Variation Consortium. Mapping human genetic diversity in Asia. *Science* 2009; **326**: 1541–5.
 - 43 Jamrozik E, Musk AW. Respiratory health issues in the Asia-Pacific region: an overview. *Respirology* 2011; **16**: 3–12. doi: 10.1111/j.1440-1843.2010.01844.x.
 - 44 Costalonga M, Herzberg MC. The oral microbiome and the immunobiology of periodontal disease and caries. *Immunol. Lett.* 2014; **162**: 22–38. doi: 10.1016/j.imlet.2014.08.017.
 - 45 Cabrera-Rubio R, Garcia-Nunez M, Seto L, Anto JM, Moya A, Monso E, Mira A. Microbiome diversity in the bronchial tracts of patients with chronic obstructive pulmonary disease. *J. Clin. Microbiol.* 2012; **50**: 3562–8. doi: 10.1128/JCM.00767-12.
 - 46 Huang S, Li R, Zeng X, He T, Zhao H, Chang A, Bo C, Chen J, Yang F, Knight R *et al.* Predictive modeling of gingivitis severity and susceptibility via oral microbiota. *ISME J.* 2014; **8**: 1768–80.
 - 47 Lim MY, Yoon HS, Rho M, Sung J, Song YM, Lee K, Ko G. Analysis of the association between host genetics, smoking, and sputum microbiota in healthy humans. *Sci. Rep.* 2016; **6**: 23745.
 - 48 Chong CW, Ahmad AF, Lim YA, Teh CS, Yap IK, Lee SC, Chin YT, Loke P, Chua KH. Effect of ethnicity and socioeconomic variation to the gut microbiota composition among pre-adolescent in Malaysia. *Sci. Rep.* 2015; **5**: 13338.
 - 49 Chotirmall SH, Burke CM. Aging and the microbiome: implications for asthma in the elderly? *Expert Rev. Respir. Med.* 2015; **9**: 125–8.
 - 50 Wu J, Liu W, He L, Huang F, Chen J, Cui P, Shen Y, Zhao J, Wang W, Zhang Y *et al.* Sputum microbiota associated with new, recurrent and treatment failure tuberculosis. *PLoS One* 2013; **8**: e83445.
 - 51 Nakayama J, Watanabe K, Jiang J, Matsuda K, Chao SH, Haryono P, La-Ongkham O, Sarwoko MA, Sujaya IN, Zhao L *et al.* Diversity in gut bacterial community of school-age children in Asia. *Sci. Rep.* 2015; **5**: 8397.
 - 52 Zhang J, Guo Z, Lim AA, Zheng Y, Koh EY, Ho D, Qiao J, Huo D, Hou Q, Huang W *et al.* Mongolians core gut microbiota and its correlation with seasonal dietary changes. *Sci. Rep.* 2014; **4**: 5001.
 - 53 Ghosh TS, Gupta SS, Bhattacharya T, Yadav D, Barik A, Chowdhury A, Das B, Mande SS, Nair GB. Gut microbiomes of Indian children of varying nutritional status. *PLoS One* 2014; **9**: e95547.
 - 54 Vogtmann E, Flores R, Yu G, Freedman ND, Shi J, Gail MH, Dye BA, Wang GQ, Klepac-Ceraj V, Paster BJ *et al.* Association between tobacco use and the upper gastrointestinal microbiome among Chinese men. *Cancer Causes Control* 2015; **26**: 581–8.
 - 55 Tyakht AV, Kostyukova ES, Popenko AS, Belenikin MS, Pavlenko AV, Larin AK, Karpova IY, Selezneva OV, Semashko TA, Ospanova EA *et al.* Human gut microbiota community structures in urban and rural populations in Russia. *Nat. Commun.* 2013; **4**: 2469.
 - 56 Hisada T, Endoh K, Kuriki K. Inter- and intra-individual variations in seasonal and daily stabilities of the human gut microbiota in Japanese. *Arch. Microbiol.* 2015; **197**: 919–34.
 - 57 Han K, Bose S, Wang JH, Kim BS, Kim MJ, Kim EJ, Kim H. Contrasting effects of fresh and fermented kimchi consumption on gut microbiota composition and gene expression related to metabolic syndrome in obese Korean women. *Mol. Nutr. Food Res.* 2015; **59**: 1004–8.
 - 58 O'Mahony C, Scully P, O'Mahony D, Murphy S, O'Brien F, Lyons A, Sherlock G, MacSharry J, Kiely B, Shanahan F *et al.* Commensal-induced regulatory T cells mediate protection against pathogen-stimulated NF-kappaB activation. *PLoS Pathog.* 2008; **4**: e1000112.
 - 59 Yatsunenkov T, Rey FE, Manary MJ, Trehan I, Dominguez-Bello MG, Contreras M, Magris M, Hidalgo G, Baldassano RN, Anokhin AP *et al.* Human gut microbiome viewed across age and geography. *Nature* 2012; **486**: 222–7.
 - 60 Suzuki TA, Worobey M. Geographical variation of human gut microbial composition. *Biol. Lett.* 2014; **10**: 20131037.
 - 61 Goodrich JK, Waters JL, Poole AC, Sutter JL, Koren O, Blekman R, Beaumont M, Van Treuren W, Knight R, Bell JT *et al.* Human genetics shape the gut microbiome. *Cell* 2014; **159**: 789–99.
 - 62 Takeshita T, Matsuo K, Furuta M, Shibata Y, Fukami K, Shimazaki Y, Akifusa S, Han DH, Kim HD, Yokoyama T *et al.* Distinct composition of the oral indigenous microbiota in South Korean and Japanese adults. *Sci. Rep.* 2014; **4**: 6990.
 - 63 Zhang X, Zhang D, Jia H, Feng Q, Wang D, Liang D, Wu X, Li J, Tang L, Li Y *et al.* The oral and gut microbiomes are perturbed in

- rheumatoid arthritis and partly normalized after treatment. *Nat. Med.* 2015; **21**: 895–905.
- 64 Rogers GB, van der Gast CJ, Serisier DJ. Predominant pathogen competition and core microbiota divergence in chronic airway infection. *ISME J.* 2015; **9**: 217–25.
 - 65 Hosgood HD 3rd, Sapkota AR, Rothman N, Rohan T, Hu W, Xu J, Vermeulen R, He X, White JR, Wu G *et al.* The potential role of lung microbiota in lung cancer attributed to household coal burning exposures. *Environ. Mol. Mutagen.* 2014; **55**: 643–51.
 - 66 Cheung MK, Lam WY, Fung WY, Law PT, Au CH, Nong W, Kam KM, Kwan HS, Tsui SK. Sputum microbiota in tuberculosis as revealed by 16S rRNA pyrosequencing. *PLoS One* 2013; **8**: e54574.
 - 67 Rogers GB, van der Gast CJ, Cuthbertson L, Thomson SK, Bruce KD, Martin ML, Serisier DJ. Clinical measures of disease in adult non-CF bronchiectasis correlate with airway microbiota composition. *Thorax* 2013; **68**: 731–7.
 - 68 Rogers GB, Zain NM, Bruce KD, Burr LD, Chen AC, Rivett DW, McGuckin MA, Serisier DJ. A novel microbiota stratification system predicts future exacerbations in bronchiectasis. *Ann. Am. Thorac. Soc.* 2014; **11**: 496–503.
 - 69 Keicho N, Hijikata M. Genetic predisposition to diffuse pan-bronchiolitis. *Respirology* 2011; **16**: 581–8. doi: 10.1111/j.1440-1843.2011.01946.x.
 - 70 Lin X, Lu J, Yang M, Dong BR, Wu HM. Macrolides for diffuse panbronchiolitis. *Cochrane Database Syst. Rev.* 2015; **1**: CD007716. doi: 10.1002/14651858.CD007716.pub4.
 - 71 Candela M, Maccaferri S, Turroni S, Carnevali P, Brigidi P. Functional intestinal microbiome, new frontiers in prebiotic design. *Int. J. Food Microbiol.* 2010; **140**: 93–101.
 - 72 Rios-Covian D, Gueimonde M, Duncan SH, Flint HJ, de los Reyes-Gavilan CG. Enhanced butyrate formation by cross-feeding between *Faecalibacterium prausnitzii* and *Bifidobacterium adolescentis*. *FEMS Microbiol. Lett.* 2015; **362**. doi: 10.1093/femsle/fnv176.
 - 73 Hrnčir T, Stepankova R, Kozakova H, Hudcovic T, Tlaskalova-Hogenova H. Gut microbiota and lipopolysaccharide content of the diet influence development of regulatory T cells: studies in germ-free mice. *BMC Immunol.* 2008; **9**: 65.
 - 74 Rhee KJ, Sethupathi P, Driks A, Lanning DK, Knight KL. Role of commensal bacteria in development of gut-associated lymphoid tissues and preimmune antibody repertoire. *J. Immunol.* 2004; **172**: 1118–24.
 - 75 Thorburn AN, Hansbro PM. Harnessing regulatory T cells to suppress asthma: from potential to therapy. *Am. J. Respir. Cell Mol. Biol.* 2010; **43**: 511–9.
 - 76 Shimada Y, Kinoshita M, Harada K, Mizutani M, Masahata K, Kayama H, Takeda K. Commensal bacteria-dependent indole production enhances epithelial barrier function in the colon. *PLoS One* 2013; **8**: e80604.
 - 77 Fukuda S, Toh H, Hase K, Oshima K, Nakanishi Y, Yoshimura K, Tobe T, Clarke JM, Topping DL, Suzuki T *et al.* Bifidobacteria can protect from enteropathogenic infection through production of acetate. *Nature* 2011; **469**: 543–7.
 - 78 Maslowski KM, Vieira AT, Ng A, Kranich J, Sierro F, Yu D, Schilter HC, Rolph MS, Mackay F, Artis D *et al.* Regulation of inflammatory responses by gut microbiota and chemoattractant receptor GPR43. *Nature* 2009; **461**: 1282–6.
 - 79 Kummeling I, Stelma FF, Dagnelie PC, Snijders BE, Penders J, Huber M, van Ree R, van den Brandt PA, Thijs C. Early life exposure to antibiotics and the subsequent development of eczema, wheeze, and allergic sensitization in the first 2 years of life: the KOALA Birth Cohort Study. *Pediatrics* 2007; **119**: e225–31.
 - 80 Penders J, Thijs C, van den Brandt PA, Kummeling I, Snijders B, Stelma F, Adams H, van Ree R, Stobberingh EE. Gut microbiota composition and development of atopic manifestations in infancy: the KOALA Birth Cohort Study. *Gut* 2007; **56**: 661–7.
 - 81 Preston JA, Thorburn AN, Starkey MR, Beckett EL, Horvat JC, Wade MA, O'Sullivan BJ, Thomas R, Beagley KW, Gibson PG *et al.* Streptococcus pneumoniae infection suppresses allergic airways disease by inducing regulatory T-cells. *Eur. Respir. J.* 2011; **37**: 53–64.
 - 82 Eiseman B, Silen W, Bascom GS, Kauvar AJ. Fecal enema as an adjunct in the treatment of pseudomembranous enterocolitis. *Surgery* 1958; **44**: 854–9.
 - 83 Zhang F, Luo W, Shi Y, Fan Z, Ji G. Should we standardize the 1,700-year-old fecal microbiota transplantation? *Am. J. Gastroenterol.* 2012; **107**: 1755; author reply p.1755–6.
 - 84 Britton RA, Young VB. Role of the intestinal microbiota in resistance to colonization by *Clostridium difficile*. *Gastroenterology* 2014; **146**: 1547–53.
 - 85 Lawley TD, Clare S, Walker AW, Stares MD, Connor TR, Raisen C, Goulding D, Rad R, Schreiber F, Brandt C *et al.* Targeted restoration of the intestinal microbiota with a simple, defined bacteriotherapy resolves relapsing *Clostridium difficile* disease in mice. *PLoS Pathog.* 2012; **8**: e1002995.
 - 86 Petrof EO, Gloor GB, Vanner SJ, Weese SJ, Carter D, Daigneault MC, Brown EM, Schroeter K, Allen-Vercos E. Stool substitute transplant therapy for the eradication of *Clostridium difficile* infection: 'RePOOPulating' the gut. *Microbiome* 2013; **1**: 3.
 - 87 Ortqvist AK, Lundholm C, Kieler H, Ludvigsson JF, Fall T, Ye W, Almquist C. Antibiotics in fetal and early life and subsequent childhood asthma: nationwide population based study with sibling analysis. *BMJ* 2014; **349**: g6979.
 - 88 Essilfie AT, Horvat JC, Kim RY, Mayall JR, Pinkerton JW, Beckett EL, Starkey MR, Simpson JL, Foster PS, Gibson PG *et al.* Macrolide therapy suppresses key features of experimental steroid-sensitive and steroid-insensitive asthma. *Thorax* 2015; **70**: 458–67.
 - 89 Rutten EP, Lenaerts K, Buurman WA, Wouters EF. Disturbed intestinal integrity in patients with COPD: effects of activities of daily living. *Chest* 2014; **145**: 245–52.
 - 90 Biedermann L, Zeitz J, Mwinyi J, Sutter-Minder E, Rehman A, Ott SJ, Steurer-Stey C, Frei A, Frei P, Scharl M *et al.* Smoking cessation induces profound changes in the composition of the intestinal microbiota in humans. *PLoS One* 2013; **8**: e59260.
 - 91 Gold MJ, Hiebert PR, Park HY, Stefanowicz D, Le A, Starkey MR, Deane A, Brown AC, Liu G, Horvat JC *et al.* Mucosal production of uric acid by airway epithelial cells contributes to particulate matter-induced allergic sensitization. *Mucosal Immunol.* 2016; **9**: 809–20.
 - 92 Kish L, Hotte N, Kaplan GG, Vincent R, Tso R, Ganzle M, Rioux KP, Thiesen A, Barkema HW, Wine E *et al.* Environmental particulate matter induces murine intestinal inflammatory responses and alters the gut microbiome. *PLoS One* 2013; **8**: e62220.
 - 93 Hirota JA, Gold MJ, Hiebert PR, Parkinson LG, Wee T, Smith D, Hansbro PM, Carlsten C, VanEeden S, Sin DD *et al.* The nucleotide-binding domain, leucine-rich repeat protein 3 inflammasome/IL-1 receptor I axis mediates innate, but not adaptive, immune responses after exposure to particulate matter under 10 µM. *Am. J. Respir. Cell Mol. Biol.* 2015; **52**: 96–105.
 - 94 D'Costa VM, King CE, Kalan L, Morar M, Sung WW, Schwarz C, Froese D, Zazula G, Calmels F, Debruyne R *et al.* Antibiotic resistance is ancient. *Nature* 2011; **477**: 457–61.
 - 95 Davies J. Inactivation of antibiotics and the dissemination of resistance genes. *Science* 1994; **264**: 375–82.
 - 96 Zhang L, Huang Y, Zhou Y, Buckley T, Wang HH. Antibiotic administration routes significantly influence the levels of antibiotic resistance in gut microbiota. *Antimicrob. Agents Chemother.* 2013; **57**: 3659–66.
 - 97 Jernberg C, Lofmark S, Edlund C, Jansson JK. Long-term ecological impacts of antibiotic administration on the human intestinal microbiota. *ISME J.* 2007; **1**: 56–66.
 - 98 Vasseur MV, Laurentie M, Rolland JG, Perrin-Guyomard A, Henri J, Ferran AA, Toutain PL, Bousquet-Melou A. Low or high doses of cefquinome targeting low or high bacterial inocula cure *Klebsiella pneumoniae* lung infections but differentially impact the levels of antibiotic resistance in fecal flora. *Antimicrob. Agents Chemother.* 2014; **58**: 1744–8.

- 99 Modi SR, Lee HH, Spina CS, Collins JJ. Antibiotic treatment expands the resistance reservoir and ecological network of the phage metagenome. *Nature* 2013; **499**: 219–22.
- 100 Rumbo C, Fernandez-Moreira E, Merino M, Poza M, Mendez JA, Soares NC, Mosquera A, Chaves F, Bou G. Horizontal transfer of the OXA-24 carbapenemase gene via outer membrane vesicles: a new mechanism of dissemination of carbapenem resistance genes in *Acinetobacter baumannii*. *Antimicrob. Agents Chemother.* 2011; **55**: 3084–90.
- 101 Zhang X, McDaniel AD, Wolf LE, Keusch GT, Waldor MK, Acheson DW. Quinolone antibiotics induce Shiga toxin-encoding bacteriophages, toxin production, and death in mice. *J. Infect. Dis.* 2000; **181**: 664–70.
- 102 Willner D, Furlan M, Haynes M, Schmieder R, Angly FE, Silva J, Tammadoni S, Nosrat B, Conrad D, Rohwer F. Metagenomic analysis of respiratory tract DNA viral communities in cystic fibrosis and non-cystic fibrosis individuals. *PLoS One* 2009; **4**: e7370.
- 103 Fancello L, Desnues C, Raoult D, Rolain JM. Bacteriophages and diffusion of genes encoding antimicrobial resistance in cystic fibrosis sputum microbiota. *J. Antimicrob. Chemother.* 2011; **66**: 2448–54.
- 104 Fodor AA, Klem ER, Gilpin DF, Elborn JS, Boucher RC, Tunney MM, Wolfgang MC. The adult cystic fibrosis airway microbiota is stable over time and infection type, and highly resilient to antibiotic treatment of exacerbations. *PLoS One* 2012; **7**: e45001.
- 105 Cuthbertson L, Rogers GB, Walker AW, Oliver A, Green LE, Daniels TW, Carroll MP, Parkhill J, Bruce KD, van der Gast CJ. Respiratory microbiota resistance and resilience to pulmonary exacerbation and subsequent antimicrobial intervention. *ISME J.* 2015; **10**: 1081–91.
- 106 Chotirmall SH, Smith SG, Gunaratnam C, Cosgrove S, Dimitrov BD, O'Neill SJ, Harvey BJ, Greene CM, McElvaney NG. Effect of estrogen on *Pseudomonas* mucoid and exacerbations in cystic fibrosis. *N. Engl. J. Med.* 2012; **366**: 1978–86.
- 107 Chmiel JF, Aksamit TR, Chotirmall SH, Dasenbrook EC, Elborn JS, LiPuma JJ, Ranganathan SC, Waters VJ, Ratjen FA. Antibiotic management of lung infections in cystic fibrosis. I. The microbiome, methicillin-resistant *Staphylococcus aureus*, gram-negative bacteria, and multiple infections. *Ann. Am. Thorac. Soc.* 2014; **11**: 1120–9.
- 108 Chmiel JF, Aksamit TR, Chotirmall SH, Dasenbrook EC, Elborn JS, LiPuma JJ, Ranganathan SC, Waters VJ, Ratjen FA. Antibiotic management of lung infections in cystic fibrosis. II. Nontuberculous mycobacteria, anaerobic bacteria, and fungi. *Ann. Am. Thorac. Soc.* 2014; **11**: 1298–306.
- 109 Biagi E, Nylund L, Candela M, Ostan R, Bucci L, Pini E, Nikkila J, Monti D, Satokari R, Franceschi C *et al.* Through ageing, and beyond: gut microbiota and inflammatory status in seniors and centenarians. *PLoS One* 2010; **5**: e10667.
- 110 Claesson MJ, Jeffery IB, Conde S, Power SE, O'Connor EM, Cusack S, Harris HM, Coakley M, Lakshminarayanan B, O'Sullivan O *et al.* Gut microbiota composition correlates with diet and health in the elderly. *Nature* 2012; **488**: 178–84.
- 111 Harvill ET. Cultivating our “frienemies”: viewing immunity as microbiome management. *MBio* 2013; **4**.
- 112 Russell SL, Gold MJ, Willing BP, Thorson L, McNagny KM, Finlay BB. Perinatal antibiotic treatment affects murine microbiota, immune responses and allergic asthma. *Gut Microbes* 2013; **4**: 158–64.
- 113 Vital M, Harkema JR, Rizzo M, Tiedje J, Brandenberger C. Alterations of the murine gut microbiome with age and allergic airway disease. *J. Immunol. Res.* 2015; **2015**: 892568.
- 114 Abrahamsson TR, Jakobsson HE, Andersson AF, Bjorksten B, Engstrand L, Jenmalm MC. Low gut microbiota diversity in early infancy precedes asthma at school age. *Clin. Exp. Allergy* 2014; **44**: 842–50.
- 115 Marsland BJ, Trompette A, Gollwitzer ES. The gut-lung axis in respiratory disease. *Ann. Am. Thorac. Soc.* 2015; **12**: S150–6.
- 116 Murray MA, Chotirmall SH. The impact of immunosenescence on pulmonary disease. *Mediators Inflamm.* 2015; **2015**: 692546.
- 117 Simpson JL, McDonald VM, Baines KJ, Oreo KM, Wang F, Hansbro PM, Gibson PG. Influence of age, past smoking, and disease severity on TLR2, neutrophilic inflammation, and MMP-9 levels in COPD. *Mediators Inflamm.* 2013; **2013**: 462934.
- 118 Cox MJ, Allgaier M, Taylor B, Baek MS, Huang YJ, Daly RA, Karaöz U, Andersen GL, Brown R, Fujimura KE *et al.* Airway microbiota and pathogen abundance in age-stratified cystic fibrosis patients. *PLoS One* 2010; **5**: e11044.
- 119 Hsu AC, Starkey MR, Hanish I, Parsons K, Haw TJ, Howland LJ, Barr I, Mahony JB, Foster PS, Knight DA *et al.* Targeting PI3K-p110alpha suppresses influenza virus infection in chronic obstructive pulmonary disease. *Am. J. Respir. Crit. Care Med.* 2015; **191**: 1012–23.
- 120 Beckett EL, Stevens RL, Jarnicki AG, Kim RY, Hanish I, Hansbro NG, Deane A, Keely S, Horvat JC, Yang M *et al.* A new short-term mouse model of chronic obstructive pulmonary disease identifies a role for mast cell tryptase in pathogenesis. *J. Allergy Clin. Immunol.* 2013; **131**: 752–62.
- 121 Hansbro PM, Hamilton MJ, Fricker M, Gellatly SL, Jarnicki AG, Zheng D, Frei SM, Wong GW, Hamadi S, Zhou S *et al.* Importance of mast cell Prss31/transmembrane tryptase/tryptase-gamma in lung function and experimental chronic obstructive pulmonary disease and colitis. *J. Biol. Chem.* 2014; **289**: 18214–27.
- 122 Haw TJ, Starkey MR, Nair PM, Pavlidis S, Liu G, Nguyen DH, Hsu AC, Hanish I, Kim RY, Collison AM *et al.* Tumour necrosis factor-related apoptosis-inducing ligand promotes cigarette smoke-induced experimental COPD. *Mucosal Immunol.* 2016; **9**: 859–72.
- 123 Liu G, Cooley MA, Jarnicki AG, Hsu ACY, Nair PM, Haw TJ, Fricker M, Gellatly SL, Kim RY, Inman MD *et al.* Fibulin-1 regulates the pathogenesis of tissue remodeling in respiratory diseases. *JCI Insight* 2016; **1**: e86380.
- 124 Fricker M, Deane A, Hansbro PM. Animal models of chronic obstructive pulmonary disease. *Expert Opin. Drug Discov.* 2014; **9**: 629–45.
- 125 Essilfie AT, Simpson JL, Dunkley ML, Morgan LC, Oliver BG, Gibson PG, Foster PS, Hansbro PM. Combined *Haemophilus influenzae* respiratory infection and allergic airways disease drives chronic infection and features of neutrophilic asthma. *Thorax* 2012; **67**: 588–99.
- 126 Starkey MR, Jarnicki AG, Essilfie AT, Gellatly SL, Kim RY, Brown AC, Foster PS, Horvat JC, Hansbro PM. Murine models of infectious exacerbations of airway inflammation. *Curr. Opin. Pharmacol.* 2013; **13**: 337–44.
- 127 Starkey MR, Essilfie AT, Horvat JC, Kim RY, Nguyen DH, Beagley KW, Mattes J, Foster PS, Hansbro PM. Constitutive production of IL-13 promotes early-life *Chlamydia* respiratory infection and allergic airway disease. *Mucosal Immunol.* 2013; **6**: 569–79.
- 128 Starkey MR, Nguyen DH, Essilfie AT, Kim RY, Hatchwell LM, Collison AM, Yagita H, Foster PS, Horvat JC, Mattes J *et al.* Tumour necrosis factor-related apoptosis-inducing ligand translates neonatal respiratory infection into chronic lung disease. *Mucosal Immunol.* 2014; **7**: 478–88.
- 129 King PT, Sharma R, O'Sullivan K, Selemidis S, Lim S, Radhakrishna N, Lo C, Prasad J, Callaghan J, McLaughlin P *et al.* Nontypeable *Haemophilus influenzae* induces sustained lung oxidative stress and protease expression. *PLoS One* 2015; **10**: e0120371.
- 130 Hsu AC, Parsons K, Barr I, Lowther S, Middleton D, Hansbro PM, Wark PA. Critical role of constitutive type I interferon response in bronchial epithelial cell to influenza infection. *PLoS One* 2012; **7**: e32947.
- 131 Tang FS, Hansbro PM, Burgess JK, Ammit AJ, Baines KJ, Oliver BG. A novel immunomodulatory function of neutrophils on rhinovirus-activated monocytes in vitro. *Thorax* 2016. doi: 10.1136/thoraxjnl-2015-207781.
- 132 Huang YJ, Sethi S, Murphy T, Nariya S, Boushey HA, Lynch SV. Airway microbiome dynamics in exacerbations of chronic

- obstructive pulmonary disease. *J. Clin. Microbiol.* 2014; **52**: 2813–23.
- 133 Rogers GB, Wesselingh S. Precision respiratory medicine and the microbiome. *Lancet Respir. Med.* 2016; **4**: 73–82.
- 134 van Nood E, Vrieze A, Nieuwdorp M, Fuentes S, Zoetendal EG, de Vos WM, Visser CE, Kuijper EJ, Bartelsman JF, Tijssen JG *et al.* Duodenal infusion of donor feces for recurrent *Clostridium difficile*. *N. Engl. J. Med.* 2013; **368**: 407–15.
- 135 Mortaz E, Adcock IM, Folkerts G, Barnes PJ, Paul Vos A, Garssen J. Probiotics in the management of lung diseases. *Mediators Inflamm.* 2013; **2013**: 751068.